Onco-Innovations Ltd. Initiates Key Preclinical Studies with Nucro-Technics for PNKP Inhibitor, Advancing Towards Human Trials

Reuters

07/05

Onco-Innovations Ltd. Initiates Key Preclinical Studies with Nucro-Technics for PNKP Inhibitor, Advancing Towards Human Trials

Onco-Innovations Ltd. has announced an agreement with Nucro-Technics Inc. to conduct IND-enabling studies for the company's lead drug candidate, NP/A83 (OI-83463), a polymer-encapsulated Polynucleotide Kinase Phosphatase (PNKP) inhibitor. This collaboration involves extensive preclinical testing to evaluate the drug's bioavailability, biodistribution, and pharmacokinetics, as well as its safety through Good Laboratory Practice $(GLP)$ toxicology studies. These efforts are aimed at supporting an Investigational New Drug $(IND.AU)$ application and the subsequent initiation of Phase I/II clinical trials for the treatment of advanced-stage, PTEN- or SHP-1-deficient cancers. The results of these studies, intended to meet both FDA and Health Canada standards, will be compiled for future regulatory submissions.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Onco-Innovations Ltd. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 1045951) on July 04, 2025, and is solely responsible for the information contained therein.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"澳洲华人首选美澳港股一站式交易平台 | 老虎证券","description":"澳、美、港、A股、ETF、期权一站式在线交易，超低佣金，新手也能轻松开启投资。在老虎证券， 1 美元起投资美股，24/5 无时差交易美股，澳大利亚华人信赖的在线炒股平台。","keywords":"老虎证券,老虎证券澳洲,老虎证券股票,老虎证券开户,老虎证券app,tigertrade老虎证券,股票,asx美股,炒股,券商,澳洲股票交易,澳大利亚炒股","social":{"ogDescription":"澳、美、港、A股、ETF、期权一站式在线交易，超低佣金，新手也能轻松开启投资。在老虎证券， 1 美元起投资美股，24/5 无时差交易美股，澳大利亚华人信赖的在线炒股平台。","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2549450315"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"AUS","license":"TBAU","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2549450315\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2549450315?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-07-05 06:01","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2549450315","market":"us","top_or_hot":-1,"title":"Onco-Innovations Ltd. Initiates Key Preclinical Studies with Nucro-Technics for PNKP Inhibitor, Advancing Towards Human Trials","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Onco-Innovations Ltd. Initiates Key Preclinical Studies with Nucro-Technics for PNKP Inhibitor, Advancing Towards Human Trials\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Onco-Innovations Ltd. has announced an agreement with Nucro-Technics Inc. to conduct IND-enabling studies for the company's lead drug candidate, NP/A83 (OI-83463), a polymer-encapsulated Polynucleotide Kinase Phosphatase (PNKP) inhibitor. This collaboration involves extensive preclinical testing to evaluate the drug's bioavailability, biodistribution, and pharmacokinetics, as well as its safety through Good Laboratory Practice <a href=\"https://laohu8.com/S/GLP\">$(GLP)$</a> toxicology studies. These efforts are aimed at supporting an Investigational New Drug <a href=\"https://laohu8.com/S/IND.AU\">$(IND.AU)$</a> application and the subsequent initiation of Phase I/II clinical trials for the treatment of advanced-stage, PTEN- or SHP-1-deficient cancers. The results of these studies, intended to meet both FDA and Health Canada standards, will be compiled for future regulatory submissions.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Onco-Innovations Ltd. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 1045951) on July 04, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Onco-Innovations Ltd. Initiates Key Preclinical Studies with Nucro-Technics for PNKP Inhibitor, Advancing Towards Human Trials</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nOnco-Innovations Ltd. Initiates Key Preclinical Studies with Nucro-Technics for PNKP Inhibitor, Advancing Towards Human Trials\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time smaller\">2025-07-05 06:01</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Onco-Innovations Ltd. Initiates Key Preclinical Studies with Nucro-Technics for PNKP Inhibitor, Advancing Towards Human Trials\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Onco-Innovations Ltd. has announced an agreement with Nucro-Technics Inc. to conduct IND-enabling studies for the company's lead drug candidate, NP/A83 (OI-83463), a polymer-encapsulated Polynucleotide Kinase Phosphatase (PNKP) inhibitor. This collaboration involves extensive preclinical testing to evaluate the drug's bioavailability, biodistribution, and pharmacokinetics, as well as its safety through Good Laboratory Practice <a href=\"https://laohu8.com/S/GLP\">$(GLP)$</a> toxicology studies. These efforts are aimed at supporting an Investigational New Drug <a href=\"https://laohu8.com/S/IND.AU\">$(IND.AU)$</a> application and the subsequent initiation of Phase I/II clinical trials for the treatment of advanced-stage, PTEN- or SHP-1-deficient cancers. The results of these studies, intended to meet both FDA and Health Canada standards, will be compiled for future regulatory submissions.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Onco-Innovations Ltd. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 1045951) on July 04, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK0028","symbol_name":"國家隊","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250704:nNDL5Dds1V:1","article_id":"2549450315","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2549450315","pubTimestamp":1751666499,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Onco-Innovations Ltd. Initiates Key Preclinical Studies with Nucro-Technics for PNKP Inhibitor, Advancing Towards Human Trials. Onco-Innovations Ltd. has announced an agreement with Nucro-Technics Inc. to conduct IND-enabling studies for the company's lead drug candidate, NP/A83 , a polymer-encapsulated Polynucleotide Kinase Phosphatase  inhibitor. This collaboration involves extensive preclinical testing to evaluate the drug's bioavailability, biodistribution, and pharmacokinetics, as well as its safety through Good Laboratory Practice  toxicology studies. These efforts are aimed at supporting an Investigational New Drug  application and the subsequent initiation of Phase I/II clinical trials for the treatment of advanced-stage, PTEN- or SHP-1-deficient cancers. The results of these studies, intended to meet both FDA and Health Canada standards, will be compiled for future regulatory submissions.Disclaimer: This news brief was created by Public Technologies  using generative artificia","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"300347":"泰格医药","BK0028":"国家队","LU1820825898.SGD":"Aberdeen Standard SICAV I - China A Share Equity A Acc SGD-H","BK0216":"研究试验","BK4092":"石油与天然气钻井","BK0174":"增持","PTEN":"Patterson-UTI Energy","LU1146622755.USD":"安本中国A股股票基金A Acc","BK0077":"质押式回购"},"translate_title":"Onco-Innovations Ltd.与Nucro-Technics启动PNKP抑制剂的关键临床前研究，向人体试验迈进","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"300347":0.9,"PTEN":0.9},"content_text":"Onco-Innovations Ltd. Initiates Key Preclinical Studies with Nucro-Technics for PNKP Inhibitor, Advancing Towards Human Trials\n    \n\n        Onco-Innovations Ltd. has announced an agreement with Nucro-Technics Inc. to conduct IND-enabling studies for the company's lead drug candidate, NP/A83 (OI-83463), a polymer-encapsulated Polynucleotide Kinase Phosphatase (PNKP) inhibitor. This collaboration involves extensive preclinical testing to evaluate the drug's bioavailability, biodistribution, and pharmacokinetics, as well as its safety through Good Laboratory Practice $(GLP)$ toxicology studies. These efforts are aimed at supporting an Investigational New Drug $(IND.AU)$ application and the subsequent initiation of Phase I/II clinical trials for the treatment of advanced-stage, PTEN- or SHP-1-deficient cancers. The results of these studies, intended to meet both FDA and Health Canada standards, will be compiled for future regulatory submissions.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Onco-Innovations Ltd. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 1045951) on July 04, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}